Document Detail

Icosapent ethyl for the treatment of hypertriglyceridemia.
MedLine Citation:
PMID:  23701295     Owner:  NLM     Status:  Publisher    
Introduction: Icosapent ethyl (IPE; Vascepa) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester recently approved in 2012 to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Elevated TG levels are associated with increased risk for coronary heart disease. Currently available TG-lowering agents (fibrates, niacins, omega-3 fatty acid products containing both EPA and docosahexaenoic acid [DHA]) may be associated with adverse effects such as flushing, hepatotoxicity, myopathy, elevated glucose levels, and/or increases in low-density lipoprotein cholesterol (LDL-C). Areas covered: This review describes IPE chemistry, pharmacokinetics, and clinical studies. In two Phase III randomized, placebo-controlled trials, one in patients with very high TG levels (≥ 500 mg/dL; MARINE) and the other in statin-treated patients at high cardiovascular risk with well-controlled LDL-C and residual high TG levels (≥ 200 to < 500 mg/dL; ANCHOR), IPE lowered levels of TG, non-high-density lipoprotein cholesterol, and other atherogenic lipoproteins without increasing LDL-C levels. Expert opinion: IPE is safe and effective for managing high TG levels, and it offers a new alternative with potential benefits over currently available treatments for dyslipidemia. The ongoing cardiovascular outcomes REDUCE-IT trial will provide valuable information on the efficacy of IPE to prevent cardiovascular events in high-risk patients already taking statins.
Christie M Ballantyne; Rene A Braeckman; Paresh N Soni
Related Documents :
23739465 - Technical options for the mitigation of direct methane and nitrous oxide emissions from...
25049965 - Effects of dietary supplementation of barodon, an anionic alkali mineral complex, on gr...
25385005 - Transgenic mouse milk expressing human bile salt-stimulated lipase improves the surviva...
24342685 - Effect of monensin in lactating dairy cow diets at 2 starch concentrations.
3512905 - Determining the viability of faecal bacteria present in germ-free mice.
18172225 - A study on regression of hypercholesterolemic atherosclerosis in rabbits by flax lignan...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-5-24
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  -     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-5-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center , 6565 Fannin, M.S. A-601, Houston, TX 77030 , USA +1 713 798 5034 ;
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A General Method to Measure Hall Effect in Nanowires: Examples of FeS2 and MnSi.
Next Document:  Whole-genome copy number variation analysis in anophthalmia and microphthalmia.